Le Kremlin-Bicêtre, France
NCT Number: NCT01065207
Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection
The investigators have previously described a limited group of HIV-1-infected patients, we called HIV controllers (HIC), who have been infected for more than 10 years, in whom viral replication is spontaneously controlled without any treatment. These patients are defined according to virological criteria: more than 90% of the quantifications of plasma viral load should be less than 400 RNA copies/mL. The purpose of the ANRS EP36 study was to characterize these patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
About this study
To study the virological and immunological features of these patients, a consortium of research teams has been set up. Several results were obtained (cf publications) : HIC are infected with replication-competent virus, HIV infects HIC CD4 T cells ex vivo but the CD8 T cells fully control this viral replication. This study led to set up a national observatory of the HICs. This observatory, set up from May 2006 to May 2008, has allowed to identify and include 86 HIC patients in France (about one hundred had been reported by the ANRS centers). When a patient is included, clinical data are collected and a biologic collection set up which can be used in genomic studies. The main characteristics of the patients included in the observatory are a median age at the diagnosis of HIV infection of 29 years (range 1-49), a median age at inclusion of 45 years [19-78], 42% are women, 87% are caucasians. The median year of HIV diagnosis is 1989 (1983-1999), so a median of 18 years of known HIV infection. The CD4 median between 1986 and 2008 is 762 CD4/mm3 [IQR:589-962], 3% of the 1368 measures are ≤ 350 /mm3; 23% patients have a CD4 T cell count < 500/mm3 and 6% < 350/mm3 at the inclusion consultation. The CD4 slope on this period shows a slow decrease estimated to -13 [-15,-11] CD4/mm3 per year. Between 1989 and 2007, 2% of the viral loads measured were ≥ 1000 RNA copies/mL. The viral load at inclusion is > 400 RNA copies/mL in 4%. Median viral DNA at the inclusion in the observatory is 1, 75 [1, 44-2, 07] log copies/millions PBMC.
The transformation of the observatory in a cohort CO 18 has several goals. The first one is to allow the long-term follow-up of the HIV controllers. Epidemiological, clinical, virological, and immunological data will be collected. The outcome of these patients is a major question: some patients could loose their HIC status either because of a drop in their CD4 T cell counts to a level below 200/mm3 without major viral replication or because viral replication becomes detectable. To understand the mechanisms involved in the control of the viral replication in HIC implies to study the patients in whom the viral control is lost and to compare them to the HIC in whom the control is preserved. Therefore it is of major importance to follow the patients now included in the observatory during a prolonged time. To increase the frequency of loss of control, the patients in whom the virus is controlled for at least 5 years but for less than 10 years will be included to increase the diversity of the HICs. Clinical events as neoplasias will be collected. The genomic studies will be continued with the benefits of new inclusions and european collaborations will be developed. The question of the quality-of-life of the patients HIC will be studied.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age ≥ 18 years
- able to give written consent
- who have been infected for more than 5 years
- not treated by ARV
- HIV positive serology
- Covered by French Social Security
Exclusion criteria
- Non compliance with the criteria of inclusion
- Pregnancy (inclusion can be postponed)
- Covered by French Social Security
Treatment and study plan
blood test at day one
BiologicalEpidemiological, clinical, virological, and immunological data will be collected.
Clinical events as neoplasia will be collected
Primary outcomes
-
to allow the long-term follow-up of the HIV controllers. Epidemiological, clinical, virological, and immunological data will be collected.
Secondary outcomes
-
To understand the mechanisms involved in the control of the viral replication in HIC implies to study the patients in whom the viral control is lost and to compare them to the HIC in whom the control is preserved
Sponsors and collaborators
Lead sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Other Gov
Registry information
Official study title
ANRS HIV CONTROLLERS NATIONAL OBSERVATORY
Acronym: ANRS CO18
Important dates
- Study start
- 2009
- Primary completion
- 2011
- Study completion
- 2012
- First posted
- Feb 9, 2010
- Registry last updated
- Dec 27, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
MAPS PrEP Van Study
NCT06908252
Blood-Borne Infections, Communicable Diseases
Durham, North Carolina, United States
View Trial DetailsAntiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
NCT01621347
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsTenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
NCT01322932
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsHIV Disclosure and Medication Adherence, a Pilot Study
NCT01621412
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial Details